Clinical Trial Detail

NCT ID NCT04128501
Title Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

T-cell acute lymphoblastic leukemia

Therapies

Azacitidine + Venetoclax

Age Groups: adult senior

No variant requirements are available.